Streamline Your AAV Process With The AAViator™ Production Platform: Performance In Small-Scale Culture Systems And Bench-Scale Bioreactors

Adeno-associated viruses (AAVs) are increasingly central to gene therapy development, offering a strong safety profile and durable transgene expression. As therapeutic targets expand beyond rare diseases to broader indications, the pressure to produce higher-dose, large-scale batches intensifies. This shift is driving innovation in upstream processing, where productivity must increase without compromising vector quality. Yet AAV manufacturing remains complex, which often leads to inconsistent yields and variable potency. To meet clinical timelines, developers need upstream workflows that are not only scalable and robust but also streamlined for speed. Addressing these challenges is key to unlocking the full potential of AAV-based therapies for larger patient populations.

Access the full white paper to learn more.